1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Product and Pipeline Analysis of the Global Colorectal Cancer Market 

Product and Pipeline Analysis of the Global Colorectal Cancer Market : Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level

Research Overview

This Frost & Sullivan research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research, Frost & Sullivan's expert analysts thoroughly examine the following modalities:
- targeted therapies
- cytotoxics
- cancer vaccines
- other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).
The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.

Market Overview

Strong drug pipeline continues to expand
The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.

Table Of Contents

Product and Pipeline Analysis of the Global Colorectal Cancer Market 
Table Of Contents
1 EXECUTIVE SUMMARY

Executive Summary
1. Executive Summary
2. Executive Summary
3. Executive Summary
4. Executive Summary
5. Executive Summary
6. Physician Treatment Guidelines—Lines of Therapy
7. Key Trends
8. Market Opportunities
9. Companies to Watch

2 METHODOLOGY AND SCOPE

Methodology and Scope
1. Methodology and Scope

3 MARKET OVERVIEW

Market Overview
1. Market Overview—Types of Treatment in Development
2. Market Overview—Global Incidences of CRC
3. Market Overview—US Incidence Rates by Year and Sex
4. Market Overview—Biomarker Type Segmentation
5. Market Overview—Key Mergers, Acquisitions, and Partnerships
6. Market Overview—Recent Developments

4 REVENUE FORECAST

Revenue Forecast
1. Global CRC Market—Revenue Forecast
2. Revenue Forecast Discussion
3. Revenue Forecast Discussion
4. Revenue Forecast Discussion

5 COMPETITIVE LANDSCAPE

Competitive Landscape
1. Competitive Landscape Overview
2. Competitive Landscape—Phase III to Launch
3. Competitive Landscape—Phase II
4. Competitive Landscape—Phase I

6 MARKETED PRODUCTS

Marketed Products
1. Key Marketed Products
2. Key Marketed Products
3. Key Marketed Products
4. Key Marketed Products

7 PIPELINE DRUGS ANALYSIS

Pipeline Drugs Analysis
1. Pipeline Synopsis—Phase III
2. Pipeline Synopsis—Phase III
3. Pipeline Synopsis—Phase III
4. Pipeline Synopsis—Phase III
5. Pipeline Synopsis—Phase III
6. Pipeline Synopsis—Phase II
7. Pipeline Synopsis—Phase II
8. Pipeline Synopsis—Phase II
9. Pipeline Synopsis—Phase II
10. Pipeline Synopsis—Phase II
11. Pipeline Synopsis—Phase II
12. Pipeline Synopsis—Phase II
13. Pipeline Synopsis—Phase II
14. Pipeline Synopsis—Phase II
15. Pipeline Synopsis—Phase II
16. Pipeline Synopsis—Phase II
17. Pipeline Synopsis—Phase II
18. Pipeline Synopsis—Phase II
19. Pipeline Synopsis—Phase II
20. Pipeline Synopsis—Phase I
21. Pipeline Synopsis—Phase I
22. Pipeline Synopsis—Phase I
23. Pipeline Synopsis—Phase I
24. Pipeline Synopsis—Phase I
25. Pipeline Synopsis—Phase I
26. Competitive Landscape—Pivotal Phase III Trials
27. Timeline of Key Events
28. Patent Expirations
29. Pipeline Discussion
30. Pipeline Discussion

8 PRODUCT DASHBOARD OF RECENTLY APPROVED DRUGS AND LATE-STAGE PIPELINE DRUG CANDIDATES

Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug Candidates
1. Product Dashboard: Avastin (Bevacizumab)—Genentech Inc. (Roche Group)
2. Avastin (Genentech, Roche)—SWOT Analysis
3. Product Dashboard—BBI503: Boston Biomedical
4. BBI503 (Boston Biomedical)—SWOT Analysis
5. Product Dashboard—Cyramza (ramicirumab): Eli Lilly
6. Cyramza (ramicirumab) (Eli Lilly)—SWOT Analysis
7. Product Dashboard—Erbitux (cetuximab): Eli Lilly/BMS/Merck
8. Erbitux (Eli Lilly, BMS, and Merck)—SWOT Analysis
9. Product Dashboard—Imprime PGG: Biothera
10. Imprime PGG (Biothera)—SWOT Analysis
11. Product Dashboard—Lonsurf (TAS-102): Taiho (Otsuka)
12. Lonsurf (TAS-102) (Taiho, Otsuka)—SWOT Analysis
13. Product Dashboard—MGN1703: Mologen
14. MGN1703 (Mologen)—SWOT Analysis
15. Product Dashboard—Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
16. Nintedanib (BIBF-1120, OFEV) (BI)—SWOT Analysis
17. Product Dashboard—Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
18. Stivarga (Bayer, Onyx)—SWOT Analysis
19. Product Dashboard—Zaltrap (aflibercept): Sanofi
20. Zaltrap (aflibercept) (Sanofi)—SWOT Analysis

9 CONCLUSIONS

Conclusions
1. Conclusions
2. Conclusions
3. The Last Word—3 Big Predictions
4. The Last Word—Discussion
5. Legal Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.